S Alzheimer Drug Pipeline Analysis
Published Date: October 2013 Price: Single User: US$1600
No. of Pages: 348 Corporate User: US$2880
New Market Research Report on “ US Alzheimer Drug Pipeline Analysis � added to ReportsnReports.com In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer's disease was 5.4 million in 2012. Out of this, the people aged 65 and above accounted for 5.2 million and at least 200,000 patients were younger than 65 with early?onset of Alzheimer's. It has been observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer's disease. Amongst the population in the 80+ age group, almost 45% have been detected with Alzeimer's disease. There exists strong competition in the Azheimer's disease market in the US. Due to this, the market is open to new and savvy companies. Given that there is a continuous rise in the ageing population and an expected exponential increase in Alzheimer's disease cases, these new entrants have the opportunity to capture a major share in the market through their efficient therapies and drugs. Thus, a better understanding of the underlying biology by the new entrants would lead to many new branches of treatment in different stages of clinical testing.
US Alzheimer Drug Pipeline Analysis "US Alzheimer Drug Pipeline Analysis" by Researcher gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process. Following parameters for each drug profile in development phase are covered in "US Alzheimer Drug Pipeline Analysis" research report: •Drug Profile Overview •Alternate Names for Drug •Active Indication •Phase of Development •Mechanism of Action •Brand Name •Patent Information Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=269695 . Browse more research reports on Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .
US Alzheimer Drug Pipeline Analysis •Country for Clinical Trial •Owner / Originator/ Licensee/Collaborator •Administrative Route •Drug Class •ATC Codes US Alzheimer Drug Pipeline by Clinical Phase: •Research: 28 •Preclinical: 106 •Phase 0: 3 •Phase-I: 36 •Phase-I/II: 2 •Phase-II: 25 •Phase-II/III: 3 •Phase-III: 8 •Preregistration: 2 •Marketed: 6 Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=269695 .
US Alzheimer Drug Pipeline Analysis Table Of Contents 1. US Alzheimer Disease Market Overview 2. Alzheimer Drug Clinical Phase: Research 2.1 Overview 2.2 Alzheimer Drug Profile in Clinical Phase 3. Alzheimer Drug Clinical Phase: Preclinical 3.1 Overview 3.2 Alzheimer Drug Profile in Clinical Phase 4. Alzheimer Drug Clinical Phase: Phase 0 4.1 Overview 4.2 Alzheimer Drug Profile in Clinical Phase 5. Alzheimer Drug Clinical Phase: Phase I 5.1 Overview 5.2 Alzheimer Drug Profile in Clinical Phase 6. Alzheimer Drug Clinical Phase: Phase I/II 6.1 Overview 6.2 Alzheimer Drug Profile in Clinical Phase Browse more research reports on Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .
US Alzheimer Drug Pipeline Analysis 7. Alzheimer Drug Clinical Phase: Phase II 7.1 Overview 7.2 Alzheimer Drug Profile in Clinical Phase 8. Alzheimer Drug Clinical Phase: Phase II/III 8.1 Overview 8.2 Alzheimer Drug Profile in Clinical Phase 9. Alzheimer Drug Clinical Phase: Phase III 9.1 Overview 9.2 Alzheimer Drug Profile in Clinical Phase 10. Alzheimer Drug Clinical Phase: Preregistration 10.1 Overview 10.2 Alzheimer Drug Profile in Clinical Phase 11. Marketed Alzheimer Drug 11.1 Overview 11.2 Marketed Alzheimer Drug Profile Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=269695 .
About ReportsnReports ReportsnReports.com is your single source for all market research needs. Our database includes 250,000+ syndicated market research reports from 100+ leading global publishers covering indepth analysis of over 5000 micro markets. With comprehensive information about the publishers and their report methodology, data sources, etc. we help you in your purchase decision by mapping your information needs with the most relevant available reports in our library.
Connect with us: sales@reportsandreports.com + 1 888 391 5441
Contact: sales@reportsandreports.com for further information. Contact: sales@reportsandreports.com for further information.